Exploring Extended Adjuvant Endocrine Therapy for HR+ Breast Cancer

Updated progression-free survival analysis data presented at the 2023 ASCO Annual Meeting favored the combination of nivolumab plus relatlimab in patients with melanoma.

In season 3, episode 3 of Targeted Talks, William J. Gradishar, MD, discusses the latest version of the NCCN Clinical Practice Guideline for managing early-stage breast cancer.

While the phase 2 CTEP-P9466 trial met its complete response end point, the trial missed its other co-primary end points in patients with BRAF V600–mutant metastatic melanoma.

In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.

Epcoritamab plus rituximab/lenalidomide demonstrated antitumor activity in patients with relapsed/refractory follicular lymphoma, including those with high-risk features.

Treatment with lisocabtagene maraleucel elicited encouraging responses and met the primary end point of the TRANSCEND CLL 004 trial in patients with relapsed/refractory CLL/SLL.